Bindu Sehgal, MD
Family Medicine · Westlake, OHNPI 1770550824
Payments from drug & device makers
Across 225 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$478
- Teva Pharmaceuticals USA, Inc.$424
- AbbVie$393
- Merck$335
- Lilly USA, LLC$203
- Pfizer$200
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,726100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $478 |
| Teva Pharmaceuticals USA, Inc. | 30 | $424 |
| AbbVie(2 entities) | 21 | $393 |
| Merck | 22 | $335 |
| Lilly USA, LLC | 14 | $203 |
| Pfizer | 12 | $200 |
| GSK | 11 | $174 |
| Novo Nordisk | 11 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $141 |
| Sanofi Pasteur Inc. | 7 | $124 |
| Johnson & Johnson | 6 | $108 |
| Amgen | 6 | $103 |
| Exact Sciences | 4 | $80 |
| Bayer | 4 | $78 |
| Boehringer Ingelheim | 5 | $74 |
| Organon | 2 | $70 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Painteq LLC | 1 | $56 |
| Shire North American Group Inc | 3 | $54 |
| Eisai Inc. | 2 | $43 |
| Novartis | 3 | $41 |
| Supernus Pharmaceuticals, Inc. | 3 | $38 |
| Esperion Therapeutics, Inc. | 3 | $37 |
| Ironshore Pharmaceuticals Inc. | 3 | $37 |
| Astellas Pharma US Inc | 2 | $34 |
| Organogenesis Inc. | 1 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$3,726 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 40 | $49,604 |
| EliquisApixaban | 52 | $44,971 |
| FarxigaDapagliflozin Propanediol | 25 | $34,527 |
| JardianceEmpagliflozin | 35 | $33,931 |
| XareltoRivaroxaban | 19 | $29,176 |
| MounjaroTirzepatide | 18 | $29,118 |
| JanuviaSitagliptin Phosphate | 14 | $21,191 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $14,683 |
| TrulicityDulaglutide | 13 | $12,159 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $10,268 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $6,506 |
| Metoprolol Succinate | 179 | $3,499 |
| Bupropion XlBupropion Hcl | 61 | $2,843 |
| Atorvastatin Calcium | 330 | $2,777 |
| Rosuvastatin Calcium | 242 | $2,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $478 | $55,71657 claims |
| Novo NordiskOzempic | $172 | $49,60440 claims |
| PfizerEliquis | $200 | $44,97152 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $74 | $44,19949 claims |
| Lilly USA, LLCMounjaro, Trulicity | $203 | $41,27731 claims |
| Johnson & JohnsonXarelto | $108 | $29,17619 claims |
| MerckJanuvia | $335 | $21,19114 claims |
| AbbVieSynthroid | $393 | $86725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Westlake
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.